The aetiology of T1D is largely unknown, but it is thought that a genetic predisposition, environmental factors and distinctive metabolic changes are involved in the initiation, development and ...

Empagliflozin vs placebo was associated with greater reductions in risk for cardiovascular disease among patients with type 1 diabetes. Sodium–glucose cotransporter inhibitors (SGLTis) are ...